e-Therapeutics plc Results of Annual General Meeting (7232G)
May 31 2017 - 8:01AM
UK Regulatory
TIDMETX
RNS Number : 7232G
e-Therapeutics plc
31 May 2017
e-Therapeutics plc
('e-Therapeutics' or the 'Company')
Results of Annual General Meeting
Oxford, UK, 31 May 2017 - e-Therapeutics plc (AIM: ETX) is
pleased to announce that all resolutions as set out in the Notice
of Annual General Meeting dated 8 May 2017 were duly passed by
shareholders of the Company at the Annual General Meeting held
earlier today.
-Ends-
Contacts:
e-Therapeutics plc Tel: +44 (0) 1993
Ray Barlow, CEO 883 125
Steve Medlicott, Finance Director www.etherapeutics.co.uk
Numis Securities Limited Tel: +44 (0) 207 260
Michael Meade / Freddie Barnfield 1000
(Nominated Adviser) www.numis.com
James Black (Corporate Broking)
Instinctif Partners Tel: +44 (0) 207 457
Melanie Toyne Sewell / Alex 2020
Shaw Email: e-therapeutics@instinctif.com
About e-Therapeutics plc
e-Therapeutics is a drug discovery company with a unique and
proprietary in silico discovery platform. The Company is applying
its computational platform to the discovery of new drug candidates
for which it can secure robust intellectual property rights.
The therapeutic focus of the Company's discovery activity is in
areas of complex disease with unmet medical need, including
immuno-oncology. The business model is to partner these preclinical
drug candidates.
e-Therapeutics is headquartered in Oxford. For more information
about the Company please visit www.etherapeutics.co.uk.
This information is provided by RNS
The company news service from the London Stock Exchange
END
RAGUARORBRAVOAR
(END) Dow Jones Newswires
May 31, 2017 09:01 ET (13:01 GMT)
E-therapeutics (LSE:ETX)
Historical Stock Chart
From Apr 2024 to May 2024
E-therapeutics (LSE:ETX)
Historical Stock Chart
From May 2023 to May 2024